Prevalence and prognostic impact of nonischemic late gadolinium enhancement in stress cardiac magnetic resonance.
Adenosine
/ administration & dosage
Aged
Contrast Media
Dipyridamole
/ administration & dosage
Female
Fibrosis
Heart Diseases
/ diagnostic imaging
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Myocardium
/ pathology
Perfusion Imaging
Predictive Value of Tests
Prevalence
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Vasodilator Agents
/ administration & dosage
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
20
5
2021
Statut:
ppublish
Résumé
To assess the prevalence and prognostic significance of NI-LGE in patients undergoing stress-CMR. Stress-CMR with either dipyridamole or adenosine was performed in 283 patients (228 men, 81%) including perfusion imaging, wall motion evaluation and LGE. Follow-up was completed in all enrolled patients (median time: 1850 days; interquartile range: 1225-2705 days). Composite endpoint included cardiac death, ventricular tachycardia, myocardial infarction, stroke, hospitalization for cardiac cause and coronary revascularization performed beyond 90 days from stress-CMR scans. One hundred and twelve patients (40%) had negative LGE (no-LGE), 140 patients (49%) I-LGE and 31 patients (11%) NI-LGE. Twenty-five events occurred in the no-LGE group, 68 in I-LGE and 11 in the NI-LGE group. On survival curves, patients with NI-LGE had worse prognosis than patients with no-LGE regardless of the presence of inducible perfusion defects. No significant prognostic differences were found between I-LGE and NI-LGE. NI-LGE can be detected in 11% of patients during stress-CMR providing a diagnosis of nonischemic cardiac disease. Patients with NI-LGE have worse prognosis than those with no-LGE.
Identifiants
pubmed: 33156590
doi: 10.2459/JCM.0000000000001016
pii: 01244665-202012000-00007
doi:
Substances chimiques
Contrast Media
0
Vasodilator Agents
0
Dipyridamole
64ALC7F90C
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
980-985Références
Masci PG, Bogaert J. Post myocardial infarction of the left ventricle: the course ahead seen by cardiac MRI. Cardiovasc Diagn Ther 2012; 2:113–127.
Pontone G, Andreini D, Bertella E, et al. Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study. Eur Radiol 2016; 26:2155–2165.
Parsai C, O’Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012; 14:54.
Al-Mallah MH, Shareef MN. The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy. Heart Fail Rev 2011; 16:369–380.
Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 2008; 29:480–489.
Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012; 379:453–460.
McGraw S, Romano S, Jue J, Bauml MA, Chung J, Farzaneh-Far A. Impact of stress cardiac magnetic resonance imaging on clinical care. Am J Cardiol 2016; 118:924–929.
Vincenti G, Masci PG, Monney P, et al. Stress perfusion CMR in patients with known and suspected CAD: prognostic value and optimal ischemic threshold for revascularization. JACC Cardiovasc Imaging 2017; 10:526–537.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology. Eur Heart J 2019; 00:1–71.
Bettencourt N, Chiribiri A, Schuster A, et al. Cardiac magnetic resonance myocardial perfusion imaging for detection of functionally significant obstructive coronary artery disease: a prospective study. Int J Cardiol 2013; 168:765–773.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41:407–477.
Bruder O, Wagner A, Lombardi M, et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry–multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson 2013; 15:9.
Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014; 46:517–592.
Noureldin RA, Liu S, Nacif MS, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14:17.
te Riele ASJM, Tandri H, Bluemke DA. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson 2014; 16:50.
Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93:841–842.
Masci PG, Barison A, Aquaro GD, et al. Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. Int J Cardiol 2012; 157:43–47.
Ziegler CE, Painter DM, Borawski JB, Kim RJ, Kim HW, Limkakeng AT Jr. Unexpected cardiac MRI findings in patients presenting to the emergency department for possible acute coronary syndrome. Crit Pathw Cardiol 2018; 17:167–171.
Aquaro GD, Perfetti M, Camastra G, et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. J Am Coll Cardiol 2017; 70:1977–1987.
Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012; 5:370–377.
Deac M, Alpendurada F, Fanaie F, et al. Prognostic value of cardiovascular magnetic resonance in patients with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2013; 168:3514–3521.
Masci PG, Doulaptsis C, Bertella E, et al. Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure. Circ Heart Fail 2014; 7:448–456.
Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10:54.
Steel K, Broderick R, Gandla V, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 2009; 120:1390–1400.
Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54:866–875.
Jablonowski R, Fernlund E, Aletras AH, et al. Regional stress-induced ischemia in non-fibrotic hypertrophied myocardium in young hcm patients. Pediatr Cardiol 2015; 36:1662–1669.
Sobajima M, Nozawa T, Suzuki T, et al. Impact of myocardial perfusion abnormality on prognosis in patients with non-ischemic dilated cardiomyopathy. J Cardiol 2010; 56:280–286.
Puntmann VO, Carr-White G, Jabbour A, et al. Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease. J Am Coll Cardiol 2018; 71:766–778.
Puntmann VO, Carr-White G, Jabbour A, et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. JACC Cardiovasc Imaging 2016; 9:40–50.